Subcutaneous Daratumumab Administration in the Thigh Vs Abdomen in Plasma Cell Disorders — StellaPhase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations(1 site)
United States
University of Maryland Greenebaum Comprehensive Cancer Center, Baltimore, Maryland Last updated October 2025